Read More Pharma Industry News Can Namodenoson overcome immunotherapy resistance in advanced pancreatic adenocarcinoma? Can-Fite BioPharma Ltd. advances Namodenoson into Phase 2b pancreatic cancer testing. Discover what this means for immunotherapy economics. bySoujanya RaviMay 15, 2026